Impact of continuous ambulatory peritoneal dialysis solutions and clearance of macromolecules on polymorphonuclear neutrophils.
Haag-Weber
M
M
Department of Medicine, University of Vienna, Austria.
Hörl
W H
WH
D001672:Biocompatible Materials / Q000009:adverse effects; D016207:Cytokines; D015314:Dialysis Solutions / Q000009:adverse effects*; D006801:Humans; D046911:Macromolecular Substances; D009504:Neutrophils / Q000187:drug effects*; D009895:Opsonin Proteins / Q000187:drug effects*; D010529:Peritoneal Cavity / Q000166:cytology; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010537:Peritoneum / Q000276:immunology; D011506:Proteins; D014118:Toxins, Biological
D001672:Biocompatible Materials; D016207:Cytokines; D015314:Dialysis Solutions; D046911:Macromolecular Substances; D009895:Opsonin Proteins; D011506:Proteins; D014118:Toxins, Biological; C089304:degranulation inhibiting protein, human; C085114:granulocyte inhibitory protein, human